|
US2488564A
(en)
|
1947-06-03 |
1949-11-22 |
Orthe Pharmaecutlcal Corp |
Preparation of hyaluronidase
|
|
US2488565A
(en)
|
1947-06-04 |
1949-11-22 |
Ortho Pharma Corp |
Preparation of hyaluronidase
|
|
US2676139A
(en)
|
1950-09-01 |
1954-04-20 |
American Home Prod |
Hyaluronidase
|
|
US2808362A
(en)
|
1952-05-02 |
1957-10-01 |
Armour & Co |
Preparation of hyaluronidase
|
|
US2795529A
(en)
|
1954-06-17 |
1957-06-11 |
American Home Prod |
Stabilized hyaluronidase solution containing calcium chloride
|
|
US2806815A
(en)
|
1955-04-12 |
1957-09-17 |
Ortho Pharma Corp |
Stabilized hyaluronidase
|
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3630200A
(en)
|
1969-06-09 |
1971-12-28 |
Alza Corp |
Ocular insert
|
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US3847770A
(en)
|
1972-04-10 |
1974-11-12 |
Continental Can Co |
Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
|
|
US4044126A
(en)
|
1972-04-20 |
1977-08-23 |
Allen & Hanburys Limited |
Steroidal aerosol compositions and process for the preparation thereof
|
|
GB1429184A
(en)
|
1972-04-20 |
1976-03-24 |
Allen & Hanburys Ltd |
Physically anti-inflammatory steroids for use in aerosols
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4002531A
(en)
|
1976-01-22 |
1977-01-11 |
Pierce Chemical Company |
Modifying enzymes with polyethylene glycol and product produced thereby
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
GB8322007D0
(en)
|
1983-08-16 |
1983-09-21 |
Wellcome Found |
Pharmaceutical delivery system
|
|
US4952496A
(en)
|
1984-03-30 |
1990-08-28 |
Associated Universities, Inc. |
Cloning and expression of the gene for bacteriophage T7 RNA polymerase
|
|
US4769027A
(en)
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
DE122010000006I2
(de)
|
1989-02-21 |
2012-06-21 |
Univ Washington |
Modifizierte formen von fortpflanzungshormonen.
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
|
US5324844A
(en)
|
1989-04-19 |
1994-06-28 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
US5349001A
(en)
|
1993-01-19 |
1994-09-20 |
Enzon, Inc. |
Cyclic imide thione activated polyalkylene oxides
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
WO1994028024A1
(en)
|
1993-06-01 |
1994-12-08 |
Enzon, Inc. |
Carbohydrate-modified polymer conjugates with erythropoietic activity
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US5605976A
(en)
|
1995-05-15 |
1997-02-25 |
Enzon, Inc. |
Method of preparing polyalkylene oxide carboxylic acids
|
|
US5919455A
(en)
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US5446090A
(en)
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
|
EE9600121A
(et)
|
1994-03-31 |
1997-04-15 |
Amgen Inc. |
Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
|
|
US5795569A
(en)
|
1994-03-31 |
1998-08-18 |
Amgen Inc. |
Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5747027A
(en)
|
1995-04-07 |
1998-05-05 |
The Regents Of The University Of California |
BH55 hyaluronidase
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5756593A
(en)
|
1995-05-15 |
1998-05-26 |
Enzon, Inc. |
Method of preparing polyalkyene oxide carboxylic acids
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
US5672662A
(en)
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
|
JPH11514853A
(ja)
|
1995-09-08 |
1999-12-21 |
ジエンザイム コーポレイション |
遺伝子治療のための改良されたａａｖベクター
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
US5747322A
(en)
|
1996-05-09 |
1998-05-05 |
The Regents Of The University Of California |
Recombinant crab collagenase
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
|
US6258351B1
(en)
|
1996-11-06 |
2001-07-10 |
Shearwater Corporation |
Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
WO1998035039A1
(en)
*
|
1997-02-06 |
1998-08-13 |
Human Genome Sciences, Inc. |
Dendritic cell-derived growth factor
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
|
CA2300957A1
(en)
|
1997-08-15 |
1999-02-25 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
JP2001517454A
(ja)
|
1997-09-19 |
2001-10-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
|
|
US20050158273A1
(en)
|
1997-09-25 |
2005-07-21 |
Harris J. M. |
Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
US6448369B1
(en)
|
1997-11-06 |
2002-09-10 |
Shearwater Corporation |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
|
US6180095B1
(en)
|
1997-12-17 |
2001-01-30 |
Enzon, Inc. |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
|
|
WO1999030727A1
(en)
|
1997-12-17 |
1999-06-24 |
Enzon, Inc. |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
|
|
US5985263A
(en)
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
|
US5965119A
(en)
|
1997-12-30 |
1999-10-12 |
Enzon, Inc. |
Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
|
|
US6624142B2
(en)
|
1997-12-30 |
2003-09-23 |
Enzon, Inc. |
Trimethyl lock based tetrapartate prodrugs
|
|
CA2323048C
(en)
|
1998-03-12 |
2006-10-10 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) derivatives with proximal reactive groups
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6153655A
(en)
|
1998-04-17 |
2000-11-28 |
Enzon, Inc. |
Terminally-branched polymeric linkers and polymeric conjugates containing the same
|
|
US6824766B2
(en)
|
1998-04-17 |
2004-11-30 |
Enzon, Inc. |
Biodegradable high molecular weight polymeric linkers and their conjugates
|
|
US6251382B1
(en)
|
1998-04-17 |
2001-06-26 |
Enzon, Inc. |
Biodegradable high molecular weight polymeric linkers and their conjugates
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
WO2000002017A2
(en)
|
1998-07-03 |
2000-01-13 |
Neles Field Controls Oy |
Method and arrangement for measuring fluid
|
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6461802B1
(en)
|
1999-08-02 |
2002-10-08 |
Agfa-Gevaert |
Adhesive layer for polyester film
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
CA2394980C
(en)
|
1999-12-22 |
2008-05-13 |
Shearwater Corporation |
Sterically hindered derivatives of water soluble polymers
|
|
WO2001045737A2
(en)
|
1999-12-22 |
2001-06-28 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
US6413507B1
(en)
|
1999-12-23 |
2002-07-02 |
Shearwater Corporation |
Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
|
|
JP4810042B2
(ja)
|
2000-01-21 |
2011-11-09 |
バイオヴェックス リミテッド |
ヘルペスウイルス株
|
|
US6602498B2
(en)
|
2000-02-22 |
2003-08-05 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
|
US6586398B1
(en)
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
AU2001258536A1
(en)
|
2000-05-16 |
2001-11-26 |
Lipoxen Technologies Limited |
Derivatisation of proteins in aqueous solution
|
|
NZ522847A
(en)
|
2000-05-16 |
2004-11-26 |
Bolder Biotechnology Inc |
Methods for refolding proteins containing free cysteine residues
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
EP1345628B1
(en)
|
2000-12-20 |
2011-04-13 |
F. Hoffmann-La Roche AG |
Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
|
|
TWI246524B
(en)
|
2001-01-19 |
2006-01-01 |
Shearwater Corp |
Multi-arm block copolymers as drug delivery vehicles
|
|
US20020096037A1
(en)
|
2001-01-25 |
2002-07-25 |
Richard Muller |
Color-coded melody text and method of teaching
|
|
US6888319B2
(en)
|
2001-03-01 |
2005-05-03 |
Palomar Medical Technologies, Inc. |
Flashlamp drive circuit
|
|
US7211395B2
(en)
|
2001-03-09 |
2007-05-01 |
Dyax Corp. |
Serum albumin binding moieties
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
US20040106794A1
(en)
|
2001-04-16 |
2004-06-03 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
|
NZ527687A
(en)
|
2001-05-11 |
2005-10-28 |
Wellstat Biolog Corp Formerly |
Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
|
|
IL149701A0
(en)
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
|
CA2452517A1
(en)
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
|
EP1446438A2
(en)
|
2001-11-07 |
2004-08-18 |
Nektar Therapeutics Al, Corporation |
Branched polymers and their conjugates
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2479212A1
(en)
|
2002-03-15 |
2003-09-25 |
Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
|
WO2003082200A2
(en)
|
2002-03-27 |
2003-10-09 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
US20050220818A1
(en)
|
2002-06-21 |
2005-10-06 |
Wellstat Biologics Corporation |
Administration of therapeutic viruses
|
|
US7122189B2
(en)
|
2002-08-13 |
2006-10-17 |
Enzon, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
|
US7087229B2
(en)
|
2003-05-30 |
2006-08-08 |
Enzon Pharmaceuticals, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
CA2498297A1
(en)
|
2002-09-09 |
2004-03-18 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
|
US7569214B2
(en)
|
2002-09-09 |
2009-08-04 |
Nektar Therapeutics Al, Corporation |
Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
NZ521851A
(en)
|
2002-10-08 |
2005-02-25 |
Auckland Uniservices Ltd |
Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
|
|
ATE480562T1
(de)
|
2002-10-15 |
2010-09-15 |
Facet Biotech Corp |
Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
|
|
KR20040040782A
(ko)
|
2002-11-08 |
2004-05-13 |
선바이오(주) |
신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
EP1596887B1
(en)
|
2003-02-26 |
2022-03-23 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
EP1599598A4
(en)
|
2003-03-04 |
2007-08-08 |
Yeda Res & Dev |
PON POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, AND COMPOSITIONS AND METHODS USING THE SAME
|
|
EP2330213A1
(en)
|
2003-03-05 |
2011-06-08 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
ATE539162T1
(de)
|
2003-03-27 |
2012-01-15 |
Ottawa Hospital Res Inst |
Mutierte viren der vesikulären stomatitis und deren verwendung
|
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
KR100512483B1
(ko)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
|
PT2644206T
(pt)
|
2003-05-23 |
2019-07-10 |
Nektar Therapeutics |
Derivados de peg contendo duas cadeias de peg
|
|
WO2005000099A2
(en)
*
|
2003-06-09 |
2005-01-06 |
Genzyme Corporation |
BLOOD FACTOR DOMAINS (BFDs)
|
|
EP1654290B1
(en)
|
2003-08-12 |
2019-03-13 |
Lipoxen Technologies Limited |
Sialic acid derivatives for protein derivatisation and conjugation
|
|
EP1668143B1
(en)
|
2003-09-30 |
2013-03-20 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
JP2007511216A
(ja)
|
2003-11-17 |
2007-05-10 |
クルセイド ラボラトリーズ リミテッド |
変異ウイルス
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
JP4762156B2
(ja)
|
2004-01-12 |
2011-08-31 |
アプライド モレキュラー エボリューション，インコーポレイテッド |
Ｆｃ領域変異体
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2005118799A1
(en)
|
2004-04-15 |
2005-12-15 |
Ista Pharmaceuticals, Inc. |
Ovine hyaluronidase
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
US20070166281A1
(en)
|
2004-08-21 |
2007-07-19 |
Kosak Kenneth M |
Chloroquine coupled antibodies and other proteins with methods for their synthesis
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
CA2602316A1
(en)
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
EP2963118B1
(en)
|
2005-06-01 |
2017-08-09 |
California Institute of Technology |
Method of targeted gene delivery using viral vectors
|
|
US8986672B2
(en)
|
2005-06-23 |
2015-03-24 |
The University Of Houston |
Use of mutant Herpes Simplex Virus-2 for cancer therapy
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
CA2618476A1
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
US7301003B2
(en)
|
2005-08-26 |
2007-11-27 |
Enzon Pharmaceuticals, Inc. |
Method of preparing polymers having terminal amine groups
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US7601798B2
(en)
|
2005-10-04 |
2009-10-13 |
Enzon Pharmaceuticals, Inc. |
Methods of preparing polymers having terminal amine groups using protected amine salts
|
|
US7989554B2
(en)
|
2006-01-10 |
2011-08-02 |
Enzon Pharmaceuticals, Inc. |
Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
|
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
|
KR20090019770A
(ko)
|
2006-03-13 |
2009-02-25 |
티아이알 테크놀로지 엘피 |
고상 조명 시스템용 적응형 제어 장치 및 전압 결정 방법
|
|
WO2007149686A2
(en)
|
2006-06-21 |
2007-12-27 |
Enzon Pharmaceuticals, Inc. |
Stabilized proteins
|
|
WO2008033413A2
(en)
|
2006-09-14 |
2008-03-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
CA2662962A1
(en)
|
2006-09-15 |
2008-03-20 |
Enzon Pharmaceuticals, Inc. |
Polyalkylene oxides having hindered ester-based biodegradable linkers
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
JP5442452B2
(ja)
|
2007-02-16 |
2014-03-12 |
ウイルツ・バイオロジクス・リミテッド |
単純ヘルペスウイルスおよびウイルス複製法
|
|
HUE027603T2
(en)
*
|
2007-04-20 |
2016-10-28 |
Sigma-Tau Rare Disease Ltd |
Stable, recombinant adenosine deaminase
|
|
PL2147122T3
(pl)
|
2007-04-20 |
2015-05-29 |
Leadiant Biosciences Ltd |
Enzymatyczna terapia przeciwnowotworowa
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US8563521B2
(en)
|
2007-06-21 |
2013-10-22 |
Technische Universitat Munchen |
Biological active proteins having increased in vivo and/or in vitro stability
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
CN101970650B
(zh)
|
2008-03-06 |
2017-07-25 |
哈洛齐梅公司 |
可溶性透明质酸酶的大规模生产
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
CN102165489B
(zh)
|
2008-09-16 |
2015-11-25 |
赫斯托克斯公司 |
生物标志物表达的可再现量化
|
|
CN102307993B
(zh)
|
2008-12-09 |
2014-06-25 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
ES2385251B1
(es)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20120134977A1
(en)
|
2009-06-01 |
2012-05-31 |
Yeda Research And Development Co. Ltd. |
Prodrugs containing albumin binding probe
|
|
PE20121539A1
(es)
|
2009-06-08 |
2012-12-06 |
Amunix Operating Inc |
Polipeptidos de la hormona de crecimiento y metodos de preparacion
|
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
EP4382170A3
(en)
|
2009-12-06 |
2024-09-04 |
Bioverativ Therapeutics Inc. |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
|
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
|
PT2591006T
(pt)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
US20130017997A1
(en)
|
2010-08-19 |
2013-01-17 |
Amunix Operating Inc. |
Factor VIII Compositions and Methods of Making and Using Same
|
|
KR20130096731A
(ko)
|
2010-09-08 |
2013-08-30 |
할로자임, 아이엔씨 |
조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
|
|
EP3115373B1
(en)
|
2010-09-08 |
2019-08-28 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Chimeric antigen receptors with an optimized hinge region
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2907504B1
(en)
|
2011-02-08 |
2017-06-28 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
JP6267644B2
(ja)
|
2011-10-20 |
2018-01-24 |
アメリカ合衆国 |
抗ｃｄ２２キメラ抗原受容体
|
|
BR112014013526A8
(pt)
|
2011-12-05 |
2017-06-13 |
Igenica Biotherapeutics Inc |
conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
|
|
SG11201403714TA
(en)
|
2011-12-30 |
2014-07-30 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
|
CA2866612C
(en)
|
2012-03-08 |
2018-01-16 |
Halozyme, Inc. |
Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
EP2997134B1
(en)
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
CA3173052A1
(en)
|
2013-08-30 |
2015-03-05 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
AU2015332533B2
(en)
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|